𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Longitudinal data analysis (repeated measures) in clinical trials

✍ Scribed by Paul S. Albert

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
227 KB
Volume
18
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis

Longitudinal data is often collected in clinical trials to examine the e!ect of treatment on the disease process over time. This paper reviews and summarizes much of the methodological research on longitudinal data analysis from the perspective of clinical trials. We discuss methodology for analysing Gaussian and discrete longitudinal data and show how these methods can be applied to clinical trials data. We illustrate these methods with "ve examples of clinical trials with longitudinal outcomes. We also discuss issues of particular concern in clinical trials including sequential monitoring and adjustments for missing data. A review of current software for analysing longitudinal data is also provided. Published in 1999 by John Wiley & Sons, Ltd. This article is a US Government work and is the public domain in the United States.

πŸ“œ SIMILAR VOLUMES

Repeated measures in clinical trials: si
Repeated measures in clinical trials: simple strategies for analysis using summary measures
✍ Stephen Senn; Lynda Stevens; Nish Chaturvedi πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 2 views

The summary measures approach to analysing repeated measures is described. The circumstances under which it can be advantageous to use such measures are considered. Strategies for baseline adjustment where there are multiple baselines are examined, as is the choice of appropriate summary statistic.

Combining mortality and longitudinal mea
Combining mortality and longitudinal measures in clinical trials
✍ Dianne M. Finkelstein; David A. Schoenfeld πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views

Clinical trials often assess therapeutic beneΓΏt on the basis of an event such as death or the diagnosis of disease. Usually, there are several additional longitudinal measures of clinical status which are collected to be used in the treatment comparison. This paper proposes a simple non-parametric t

Analysis of longitudinal data in an Alzh
Analysis of longitudinal data in an Alzheimer's disease clinical trial
✍ Ronald G. Thomas; Julie D. Berg; Mary Sano; Leon Thal πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 128 KB πŸ‘ 1 views

Evidence of delayed progression is the primary mechanism for demonstrating therapeutic e cacy in clinical trials in Alzheimer's disease. In the major trials of therapeutic treatment of AD, to date, measures based on clinical judgement and cognitive performance, instead of mortality, have been used a